Mealey's (October 5, 2018, 12:11 PM EDT) -- ALEXANDRIA, Va. — In a final written decision issued Oct. 4, the Patent Trial and Appeal Board agreed with an inter partes review (IPR) petitioner that six claims of a patented method of treating B-cell lymphomas, including non-Hodgkin’s lymphoma (NHL), would have been anticipated by or obvious to a person of skill in the art (Celltrion Inc. v. Biogen Inc., No. IPR2017-01095, PTAB)....